Dual agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
== Further reading == Davidson JA, Sloan L (January 2017). "Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview". Adv Ther. 34 (1): 41–59. doi:10.1007/s12325-016-0434-2. PMC 5216068. PMID 27854055.
On 26 August 2008, Financial Times wrote that "Most accounts agree that it was South Ossetian separatists who committed the first act of escalation when they blew up a Georgian military vehicle on August 1, wounding five Georgian peacekeeping troops." It argued: "So swift was the Russian reaction that some analysts believe that, while it did not appear to precede the Georgian assault on Tskhinvali, as Mr Saakashvili claims, it may have been planned in advance, with Mr Saakashvili simply falling into a well prepared Russian trap."
Validation: Ensuring that the device meets the needs and requirements of its intended users and the intended use environment. Verification: Ensuring that the device meets its specified design requirements ISO 9001:2015 (Quality management systems requirements) makes the following distinction between the two activities, when describing design and development controls:
The most common nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The phosphate group and the sugar of each form nucleotide bonds to form the backbone of the nucleic acid, while the sequence of nitrogenous bases stores the information. The most common nitrogenous bases are adenine, cytosine, guanine, thymine, and uracil. The nitrogenous bases of each strand of a nucleic acid will form hydrogen bonds with a specific partner base in a complementary strand of nucleic acid. Adenine binds with thymine or uracil, and cytosine and guanine bind one another. Adenine, thymine, and uracil form two hydrogen bonds, while cytosine and guanine form three. Aside from the genetic material of the cell, nucleic acids often play a role as second messengers, as well as forming the base molecule for adenosine triphosphate (ATP), the primary energy-carrier molecule found in all living organisms. Other nucleotides besides adenosine can also be found forming other, less common, energy-carrying molecules such as guanosine in GTP or uracil in UTP. Also, while adenine, cytosine, and guanine occur in both RNA and DNA, thymine occurs only in DNA and uracil occurs in RNA.
=== Endocrine effects === As with other SSRIs, citalopram can cause an increase in serum prolactin level. Citalopram has no significant effect on insulin sensitivity in women of reproductive age and no changes in glycaemic control were seen in another trial.
Sources: en.wikipedia.org
==== Naloxegol ==== Naloxegol is a polyethylene glycol-modified derivative of α-naloxol. Naloxegol has a similar form as naloxone as a heteropentacyclic compound both of which have an allyl group attached to the amine of the piperidine ring. However, naloxegol has a monomethoxy-terminated n=7 oligomer of PEG connected to the 6-alpha-hydroxyl group of ɑ-naloxol via an ether linkage. The PEG moiety increases the molecular weight and therefore restricts the uptake of naloxegol into the CNS. Furthermore, pegylated naloxegol becomes a substrate for the P-glycoprotein efflux transporter that transports the compound out of the CNS.
The parathyroid glands, of which there are 4–6, are found on the back of the thyroid glands, and secrete parathyroid hormone. This causes an increase in blood calcium levels by targeting bone, the intestine, and the kidneys. The parathyroid hormone is the antagonist of calcitonin. Parathyroid hormone release is triggered by falling blood calcium levels and is inhibited by rising blood calcium levels.
== History == In 1975, Tony Tan Caktiong and his family opened a Magnolia ice cream parlor in Cubao, Quezon City. The outlet later began offering hot meals and sandwiches. When the food items became more popular than ice cream, the family decided to convert the ice cream parlor into a fast food restaurant, which became the first Jollibee outlet in 1978. Management consultant Manuel C. Lumba advised the family on the change in strategy. Jollibee was initially named "Jolibe", but changed its name to "Jollibee". Jollibee Foods Corporation (JFC) was incorporated in January 1978. By the end of that year, there were seven Jollibee branches in Metro Manila. The first franchised outlet of Jollibee opened in Santa Cruz, Manila, in 1979. Jollibee experienced rapid growth. The chain was able to withstand the entry of McDonald's into the Philippines in 1981 by focusing on the specific tastes of the Filipino market. The first provincial Jollibee outlet opened in Mabalacat, Pampanga. The first overseas Jollibee opened in Singapore in 1985 at the Katong Shopping Centre; that location closed only a year later (since returned in 2013). In the same year, Jollibee opened branches in the Middle East and Guam. Jollibee continued to expand and set up outlets both within the country and abroad. Jollibee first overseas outlet opened in Brunei Darussalam on 28 August 1987 at the Utama Bowling Centre which is still operating; 35 Jollibee personnel were sent to Bandar Seri Begawan for its first outlet.
Animal studies suggest that RB-101 is also likely to be useful in relieving the symptoms of acute opioid withdrawal and in the management of opioid dependence. A significant advantage of inhibiting the breakdown of endogenous opioid peptides rather than stimulating opioid receptors with exogenous drugs is that the levels of opioid peptides are only increased slightly from natural levels, thus avoiding overstimulation and downregulation of the opioid receptors. This means that even when RB-101 is used in high doses for extended periods of time, there is no development of dependence on the drug or tolerance to its analgesic effects. Consequently, even though RB-101 is able to produce potent analgesic effects via the opioid system, it is unlikely to be addictive. Unlike conventional opioid agonists, RB-101 also failed to produce respiratory depression, which suggests it might be a much safer drug than traditional opioid painkillers. RB-101 also powerfully potentiated the effects of traditional analgesics such as ibuprofen and morphine, suggesting that it could be used to boost the action of a low dose of normal opioids which would otherwise be ineffective. RB-101 itself is not orally active and so has not been developed for medical use in humans, however modification of the drug has led to newer orally acting compounds such as RB-120 and RB-3007, which may be more likely to be adopted for medical use if clinical trials are successful.
Sources: en.wikipedia.org
Bully: Tyler Height: 6'1" Weight: 250 lbs Victim(s): Joe and Dylan Fighter: Daniel Cormier Height: 5'11" Weight: 247 lbs Money earned by Bully: $0 Money earned by victim(s): $10,000 Original airing: This episode aired on MTV2 on September 29, 2012. In MTV Latin America, this is run as the first episode of season 3, followed by the "Michael" episode, thus omitting the episode where Mayhem fights Andy.
The arachnoid layer was first described by Dutch physician Gerardus Blasius in 1664. In 1695, Humphrey Ridley first described the subarachnoid cisterns. He also contributed to the understanding of the blood-brain barrier, and accurately described the fifth cranial nerve ganglion with its branches. In 1699, Frederick Ruysch confirmed that the arachnoid mater formed a complete layer that surrounded the brain. Its current name is based on his description of its spiderlike morphology. Arachnoid granulations were first described by Italian physician Antonio Pacchioni who published his Dissertatio Epistolaris de Glandulis Conglobatis Durae Meningis Humanae in 1705. In seven articles from 1899 to 1902, Italian anatomist Giuseppe Sterzi described comparative studies on the meninges from the lancelet to the human. He showed that the spinal meninges were very simple in adult lower vertebrates and in the early development of more advanced vertebrates.
A circuit of fluid in the loop of Henle—an important part of the kidneys—allows for gradual buildup of the concentration of urine in the kidneys, by using active transport on the exiting nephrons (tubules carrying liquid in the process of gradually concentrating the urea). The active transport pumps need only to overcome a constant and low gradient of concentration, because of the countercurrent multiplier mechanism. Various substances are passed from the liquid entering the nephrons until exiting the loop (See the nephron flow diagram). The sequence of flow is as follows:
== Function and mechanism == An amino acid contains an amino (NH2) group. A keto acid contains a keto (=O) group. In transamination, the NH2 group on one molecule is exchanged with the =O group on the other molecule. The amino acid becomes a keto acid, and the keto acid becomes an amino acid. Transaminases require the coenzyme pyridoxal phosphate, which is converted into pyridoxamine in the first half-reaction, when an amino acid is converted into a keto acid. Enzyme-bound pyridoxamine in turn reacts with pyruvate, oxaloacetate, or alpha-ketoglutarate, giving alanine, aspartic acid, or glutamic acid, respectively. Many transamination reactions occur in tissues, catalysed by transaminases specific for a particular amino/keto acid pair. The reactions are readily reversible, the direction being determined by which of the reactants are in excess. This reversibility can be exploited for synthetic chemistry applications to achieve the synthesis of valuable chiral amines. The specific enzymes are named from one of the reactant pairs, for example; the reaction between glutamic acid and pyruvic acid to make alpha ketoglutaric acid and alanine is called alanine transaminase and was originally called glutamic-pyruvic transaminase or GPT for short.
Ceremonial San Pedro use seems to be characterized by relatively strong spiritual experiences, and low incidence of challenging experiences. DMT (N,N-dimethyltryptamine) is an indole alkaloid found in various species of plants. Traditionally, it is consumed by tribes in South America in the form of ayahuasca. A brew is used that consists of DMT-containing plants as well as plants containing monoamine oxidase inhibitors (MAOIs), like harmine and harmaline, which allows DMT to be consumed orally without being rendered inactive by monoamine oxidase (MAO) enzymes in the digestive system. A pharmaceutical version of ayahuasca is called pharmahuasca. In the Western world, DMT is more commonly consumed via the vaporisation of freebase DMT. Whereas ayahuasca typically lasts for several hours, inhalation has an onset measured in seconds and has effects measured in minutes, being much more intense. Particularly in smoked or vaporised form, DMT has the ability to cause users to enter a hallucinatory realm fully detached from reality, being typically characterised by hyperbolic geometry, and described as defying visual or verbal description. Users have also reported encountering and communicating with entities within this hallucinatory state. DMT is the archetypal substituted tryptamine, being the structural scaffold of psilocybin and, to a lesser extent, the lysergamides. 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine; mebufotenin) is a naturally occurring substituted 5-methoxytryptamine which was first identified as having psychedelic effects in the 1960s.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.